Patients requiring hospitalization due to COVID-19 pneumonia (non-severe) will be randomized to standard prophylactic doses or full therapeutic dose of bemiparin (a LMWH) for 10 days.
Drug: Bemiparin sodium
Prophilactic vs full-dose for 10 days
Other Name: Hibor
Inclusion Criteria:
- Age (equal or more than 18 yo)
- Hospitalization at conventional wards due to COVID-19 related mild or moderate
pneumonia (CURB65<3 points; Sat. O2>90%)
- 3-4 points according to the WHO ordinal scale.
- Confirmed COVID-19 (PCR or other validated test)
- D-dimer >500 ng/mL
- Sign of informed consent
- The patient is able, according to investigator's opinion, to deal with all the
requirements of the clinical trial.
Exclusion Criteria:
Hospital Rey Juan Carlos
Móstoles, Madrid, Spain
Clinica Universidad de Navarra
Pamplona, Navarra, Spain
Hospital Clinic
Barcelona, Spain
Hospital Sant Pau
Barcelona, Spain
Hospital Universitario Bellvitge
L'Hospitalet De Llobregat, Spain
Fundación Jiménez Díaz
Madrid, Spain
Hospital Clínico San carlos
Madrid, Spain
Hospital Universitario La Paz
Madrid, Spain
Complejo Hospitalario de Navarra
Pamplona, Spain
Hospital Universitario de Salamanca
Salamanca, Spain
Complejo Hospitalario de Toledo
Toledo, Spain
Hospital Universitario Río Hortega
Valladolid, Spain
Ramon Lecumberri, MD, PhD
+34 948296397
rlecumber@unav.es
Ramon Lecumberri, Md, PhD, Principal Investigator
University of Navarra